The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1497
June 20, 2016
View Complete Issue         Table of Contents 2019 
Spritam - A New Formulation of Levetiracetam for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Spritam - A New Formulation of Levetiracetam for Epilepsy
June 20, 2016 (Issue: 1497)
The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug levetiracetam (Spritam – Aprecia) for adjunctive treatment of partialonset, myoclonic, and primary generalized tonicclonic seizures. Oral and intravenous...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Spritam - A New Formulation of Levetiracetam for Epilepsy
Article code: 1497b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.